Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care. The Company has pioneered stem cell research using human amniotic membrane to treat corneal surface conditions and developed Amniograft™, the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. The National Institute of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 130,000 human implants have been conducted using the Company’s patented Crotek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform.
NEOX® Wound Allograft accessible to more than 4.4 Million additional medicare lives.
AMNIOX Highlights Study Showing More Than Eighty Seven Percent of Patients With Diabetic Foot Ulcers Achieve Healing When Treated with NEOX® Wound Allograft
Amniox highlights study showing more than 87% of patients with diabetic foot ulcers achieve healing when treated with NEOX® Wound Allograft.
AMNIOX Highlights Study Showing Eighty Percent Of Patients With Lower-Extremity Ulcers Achieve Healing When Treated With NEOX Wound Allograft
AMNIOX Medical, Inc., a TissueTech, Inc., company, announced the results of A Single-Center, Retrospective Study of Cryopreserved Umbilical Cord for Wound Healing in Patients Suffering From Chronic Wounds of the Foot and Ankle, a review of the effectiveness of NEOX® Wound Allograft in treating this patient population.
TissueTech™ Receives Prestigious Tibbetts Award from Small Business Administration for Significant Achievements in Regenerative Medicine
TissueTech, a biotechnology company and leader in regenerative healing therapies, announced it was presented a prestigious Tibbetts Award by the U.S. SBA.
TissueTech, Inc. receives $15 million in growth equity financing from River Cities and Ballast Point.